Dianthus Therapeutics DNTH
NASDAQ DNTH
$108.10 +0.25 (+0.23%)
As of: Sep 4, 2026 · 3:59 PM EDT

Dianthus Therapeutics (DNTH) Net Cash Flow Growth (5y) (2022 - 2025)

Analysis

Dianthus Therapeutics (DNTH) Net Cash Flow Growth (5y) (2022 - 2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Dianthus Therapeutics 4.09 Bn 3.69 Bn -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 51.25%
Jun 30, 2025 -44.88%
Mar 31, 2025 -26.86%
Dec 31, 2024 11.85%
Sep 30, 2024 -49.03%
Jun 30, 2024 -59.49%
Mar 31, 2024 56.15%
Dec 31, 2023 24.47%
Sep 30, 2023 60.05%
Jun 30, 2023 -33.70%
Mar 31, 2023 22.77%
Dec 31, 2022 -20.66%
Sep 30, 2022 97.05%